Intercept Pharmaceuticals (NAS:ICPT) COGS-to-Revenue

: 0.00 (As of Jun. 2023)

View and export this data going back to 2012. Start your Free Trial

Intercept Pharmaceuticals's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.2 Mil. Its Revenue for the three months ended in Jun. 2023 was $83.7 Mil.

Intercept Pharmaceuticals's COGS to Revenue for the three months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Intercept Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2023 was 99.78%.

Intercept Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Intercept Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

0.01

0.02

0.01

Intercept Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
COGS-to-Revenue																-	0.01	-	-	-

Intercept Pharmaceuticals COGS-to-Revenue Calculation

Intercept Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.98399999999998	/	285.71
	=	0.00

Intercept Pharmaceuticals's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.185	/	83.718
	=	0.00

Intercept Pharmaceuticals (NAS:ICPT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Intercept Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.185 / 83.718
	=	99.78 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Intercept Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

305 Madison Avenue, Morristown, NJ, USA, 07960

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451